MedPath

Neoadjuvant Chemohormonal Therapy Before Radical Prostatectomy for High-Risk Prostate Cancer

A study evaluated the feasibility and safety of neoadjuvant chemohormonal therapy (NCHT) before radical prostatectomy (RP) for Japanese patients with high-risk localized prostate cancer (PCa). The study found NCHT to be safe and feasible, with a significant difference in biochemical progression-free survival (bPFS) between very high-risk (VHR) and not very high-risk (nVHR) groups. However, more extensive treatment modalities are needed to improve outcomes, especially in VHR patients.

Background

Radical prostatectomy (RP) is the standard treatment for high-risk prostate cancer (PCa), but recurrence rates are high. This study evaluated the feasibility and safety of neoadjuvant chemohormonal therapy (NCHT) before RP for Japanese patients with high-risk localized PCa.

Methods

From February 2009 to April 2016, 21 high-risk patients were enrolled in this prospective study. Patients were treated with docetaxel (70 mg/m2) every four weeks for three cycles and luteinizing hormone-releasing hormone agonist. Dose reductions were applied for grade 3–4 toxicities.

Results

The median follow-up was 88.6 months. The dose of docetaxel was reduced in 13 patients. The estimated five-year biochemical progression-free survival (bPFS) rate was 57.1%. There was a significant difference in bPFS between the nVHR and VHR groups (p = 0.023), with five-year bPFS rates of 76.9% and 25.0%, respectively.

Conclusions

NCHT was found to be safe and feasible, with a better bPFS rate observed in the nVHR group. However, NCHT was not acceptable to improve bPFS in patients with VHR PCa, indicating the need for additional treatment modalities to improve outcomes in VHR patients.

Keywords

prostate cancer, neoadjuvant chemohormonal therapy, radical prostatectomy
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Neoadjuvant Therapies Show Promise in High-Risk Localized Prostate Cancer

Phase II trials suggest that androgen deprivation therapy (ADT) combined with second-generation agents shows promise, with favorable pathological complete response (pCR) and minimal residual disease (MRD) rates.

Intensified Total Neoadjuvant Therapy Shows Promise in Locally Advanced Rectal Cancer with 74.6% Five-Year Survival Rate

A phase II clinical trial evaluating intensified total neoadjuvant therapy (TNT) in locally advanced rectal cancer demonstrated encouraging long-term results with a 74.6% five-year overall survival rate. The study showed particularly promising outcomes for complete responders, who achieved an 81.8% disease-free survival rate at five years.

Risk-Adapted Therapy Shows Promise in Muscle-Invasive Bladder Cancer

A phase II trial evaluated risk-adapted therapy after neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC).

Radiomics Model Predicts Pathological Response to Neoadjuvant Therapy in Hepatocellular Carcinoma

A novel radiomics model, utilizing CT imaging features, effectively predicts pathological complete response (pCR) in initially unresectable hepatocellular carcinoma (HCC) after neoadjuvant conversion therapy.

Neoadjuvant Immunochemoradiotherapy Shows Similar Efficacy to Chemoradiotherapy in ESCC

A multicenter retrospective study compared neoadjuvant immunochemoradiotherapy (NICRT) and neoadjuvant chemoradiotherapy (NCRT) for locally advanced esophageal squamous cell carcinoma (ESCC).

Nivolumab Plus Radiotherapy Improves Outcomes in High-Risk Prostate Cancer

A phase 2 trial showed that adding nivolumab to standard radiotherapy significantly improved freedom from biochemical recurrence (FFBR) in patients with Gleason grade group 5 prostate cancer.

Transdermal Estradiol Shows Promise as Alternative to LHRH Agonists in High-Risk Prostate Cancer

A phase 3 study presented at ESMO 2024 indicates transdermal estradiol (tE2) is as effective as LHRH agonists for androgen suppression in high-risk, non-metastatic prostate cancer.

Neoadjuvant Chemotherapy Shows Promise in Nasal and Paranasal Sinus Cancer

A phase 2 trial (EA3163) suggests neoadjuvant chemotherapy may improve organ preservation in T3/T4a NPNSCC patients.

De-escalated Therapy Shows Excellent Survival in HR+/HER2+ Breast Cancer

Patients with HR+/HER2+ early breast cancer achieved excellent survival outcomes with neoadjuvant endocrine therapy or chemotherapy plus trastuzumab and pertuzumab.

Neoadjuvant Chemohormonal Therapy Shows Promise for High-Risk Prostate Cancer

Recent studies suggest that neoadjuvant chemohormonal therapy (NCHT) could improve outcomes for patients with high-risk localized prostate cancer (PCa). Despite the potential for increased adverse events and economic burdens, NCHT, particularly with the addition of docetaxel, has shown to be effective in reducing tumor burden and improving survival rates. The importance of patient selection, pathological response evaluation, and the use of predictive biomarkers and PSMA PET/CT imaging are highlighted as crucial factors in optimizing treatment strategies.

Reference News

[1]
Neoadjuvant Chemohormonal Therapy before Radical ...
pmc.ncbi.nlm.nih.gov · Apr 9, 2021

Neoadjuvant chemohormonal therapy (NCHT) before radical prostatectomy (RP) was evaluated for Japanese patients with high...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy